| Literature DB >> 32676557 |
Christian Vassallo1, Andrew A Borg1, Daniel Farrugia2, Cecilia Mercieca1.
Abstract
OBJECTIVE/AIM: Septic arthritis is an uncommon but important disease with significant morbidity and mortality, especially if inadequately managed. The aim of this epidemiological study was to identify the characteristics and outcomes of patients treated for septic arthritis at Mater Dei Hospital, Malta, over a 10-year period.Entities:
Keywords: Epidemiology; infection; mortality; risk factors; septic arthritis
Year: 2020 PMID: 32676557 PMCID: PMC7362118 DOI: 10.31138/mjr.31.2.195
Source DB: PubMed Journal: Mediterr J Rheumatol ISSN: 2529-198X
Demographics and clinical characteristics for native and prosthetic joints.
| Number of cases | 124 | 138 | - |
| Median (IQR) age in years | 66 (41.3–75) | 69 (63–77) | <0.001 |
| Percentage of males | 62.1% | 48.6% | 0.034 |
| Number (%) of deaths | 12 (9.7%) | 13 (9.4%) | 1.000 |
| Number (%) of deaths attributed to joint sepsis | 7 (5.6%) | 8 (5.8%) | 1.000 |
| Newman Grade A | 82 (66.1%) | 113 (81.9%) | 0.004 |
| Newman Grade B | 6 (4.8%) | 8 (5.8%) | 0.789 |
| Newman Grade C | 36 (29.0%) | 17 (12.3%) | 0.001 |
| Knee | 84 (67.7%) | 86 (62.3%) | 0.368 |
| Shoulder | 12 (9.7%) | 2 (1.4%) | 0.004 |
| Hip | 7 (5.6%) | 50 (36.2%) | <0.001 |
| Elbow | 5 (4.0%) | 0 | 0.023 |
| Others | 16 (12.9%) | 0 | <0.001 |
| Mean (±SD) time to presentation | 8.3 (±6.5) days | 6.67 (±6) days | 0.021 |
| Median (IQR) time to presentation | 6 (2–14) days | 4.5 (2–14) | 0.021 |
| History of acutely hot and swollen joint | 111 (89.5%) | 112 (81.2%) | 0.081 |
| Fever | 50 (40.3%) | 55 (39.9%) | 1.000 |
| Limitation in joint movement | 102 (82.3%) | 105 (76.1%) | 0.229 |
| Leucocytosis (WCC >10×109/L ) | 83 (66.9%) | 73 (52.9%) | 0.024 |
| Mean (±SD) WCC (×109/L ) | 11.8 (±3.1) | 10.9 (±4.6) | 0.001 |
| Median (IQR) WCC (×109/L ) | 12.2 (9.7–13.5) | 10.2 (7.6–12.8) | 0.001 |
| Raised inflammatory markers | 118 (95.2%) | 134 (97.1%) | 0.524 |
| Raised CRP (>5mg/L) | 116 (93.5%) | 127 (92.0%) | 0.812 |
| Median (IQR) CRP (mg/L) | 159.5 (85.8–291) | 68.7 (20.5–186) | <0.001 |
| Raised ESR (>30mm 1st hr ) | 104 (83.9%) | 116 (84.1%) | 1.000 |
| Mean (±SD) ESR (mm 1st hr ) | 74.6 (±37.9) | 73.6 (±36.6) | 0.779 |
| Median (IQR) ESR (mm 1st hr ) | 70 (39–113) | 83 (39–108) | 0.779 |
| Osteoarthritis affecting infected joint | 38 (30.6%) | - | - |
| Diabetes mellitus | 28 (22.6%) | 34 (24.6%) | 0.771 |
| Cutaneous ulcers | 10 (8.1%) | 13 (9.4%) | 0.828 |
| Direct trauma prior to presentation | 17 (13.7%) | 12 (8.7%) | 0.238 |
| Concomitant oral glucocorticoids | 8 (6.5%) | 6 (4.3%) | 0.584 |
| Rheumatoid arthritis (RA) | 2 (1.6%) | 8 (5.8%) | 0.108 |
| Psoriasis | 2 (1.6%) | 0 | 0.223 |
| Illicit intravenous drug use | 7 (5.6%) | 0 | 0.005 |
| Recent intra-articular glucocorticoid injection | 3 (2.4%) | 0 | 0.105 |
| Recent hospitalization | 37 (29.8%) | 90 (65.2%) | <0.001 |
CRP, C-Reactive protein; ESR, Erythrocyte sedimentation rate; WCC, White cell count.
Summary of organisms cultured. Percentages for each organism cultured are based on total numbers of positive cultures for each group.
| Total number of positive cultures (Grades A+B) | 88 (71.0%) | 121 (87.7%) | 0.001 |
| Staphylococcus aureus | 54 (61.4%) | 68 (56.2%) | 0.480 |
| | 32 (36.4%) | 43 (35.5%) | 1.000 |
| | 22 (25.0%) | 25 (20.7%) | 0.504 |
| Streptococcus spp. | 15 (17.0%) | 15 (12.4%) | 0.425 |
| Gram negatives | 14 (15.9%) | 28 (23.1%) | 0.224 |
| | 5 (5.7%) | 10 (8.3%) | 0.592 |
| | 4 (4.5%) | 9 (7.4%) | 0.564 |
| | 3 (3.4%) | 10 (8.3%) | 0.245 |
| | 1 (1.1%) | 0 | 0.421 |
| | 0 | 4 (3.3%) | 0.140 |
| Coagulase negative Staphylococci | 4 (4.5%) | 28 (23.1%) | <0.001 |
| Other gram positives | 5 (5.7%) | 8 (6.6%) | 1.000 |
| Mixed infection | 7 (8.0%) | 18 (14.9%) | 0.138 |
MSSA, Methicillin sensitive Staphylococcus aureus; MRSA, Methicillin resistant Staphylococcus aureus.
Summary of treatments used.
| Median (IQR) duration of parenteral antibiotics | 14 (10–21) days | 14 (14–22) days | 0.103 |
| Median (IQR) duration of oral antibiotics | 14 (14–28) days | 90 (42–180) days | <0.001 |
| Ciprofloxacin | 48 (38.7%) | 44 (31.9%) | 0.300 |
| Clindamycin | 31 (25.0%) | 25 (18.1%) | 0.179 |
| Co-amoxiclav | 19 (15.3%) | 15 (10.9%) | 0.358 |
| Flucloxacillin | 30 (24.2%) | 12 (8.7%) | <0.001 |
| Levofloxacin | 15 (12.1%) | 53 (38.4%) | <0.001 |
| Rifampicin | 10 (8.1%) | 74 (53.6%) | <0.001 |
| Teicoplanin | 18 (14.5%) | 45 (32.6%) | <0.001 |
| Closed needle aspiration | 82 (66.1%) | - | - |
| Joint drainage and washout | 60 (48.4%) | - | - |
| Synovectomy | 14 (11.3%) | - | - |
| DAIR | - | 73 (52.9%) | - |
| Revision surgery | - | 42 (30.4%) | - |
| Excision arthroplasty | - | 11 (8.0%) | - |
DAIR, Debridement, antibiotics and implant retention.
Characteristics of patients who died from joint sepsis.
| 1 | 86 | F | DM; CHF | Finger | |
| 2 | 86 | M | DM; IHD; Hypertension | Shoulder | |
| 3 | 87 | F | DM; CHF; Hypertension | Knee | |
| 4 | 80 | F | DM; Peripheral vascular disease; Hypertension | Shoulder | |
| 5 | 81 | M | Hypertension | Knee prosthesis | |
| 6 | 68 | F | DM; CHF; Hypertension; End Stage Kidney Disease on haemodialysis | Knee | |
| 7 | 81 | F | DM; Rheumatoid arthritis; Hypertension | Hip prosthesis | |
| 8 | 67 | M | IHD; Hypertension | Knee prosthesis | |
| 9 | 85 | M | DM | Shoulder | |
| 10 | 75 | M | DM; CHF; IHD; Hypertension; CKD | Knee prosthesis | |
| 11 | 67 | M | DM; CHF; CKD | Knee prosthesis | |
| 12 | 87 | M | Hypertension | Knee prosthesis | |
| 13 | 86 | F | DM; Osteoporosis; Dementia | Knee prosthesis | |
| 14 | 85 | M | DM; Hypertension; CKD; CHF; IHD | Knee | |
| 15 | 80 | M | Hypertension; Paget’s disease; dementia | Hip prosthesis |
CHF, Congestive heart failure; CKD, Chronic kidney disease; DM, Diabetes mellitus; IHD, Ischaemic heart disease.